vk2735
Peptideexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Dec 14, 2021 (NCT05203237)
Timeline
Indications
Mechanism of action
GIPR agonist
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07104383 | Phase 3 | Jun 23, 2025 | Viking Therapeutics, Inc. |
| NCT07104500 | Phase 3 | Jun 23, 2025 | Viking Therapeutics, Inc. |
| NCT06828055 | Phase 2 | Dec 18, 2024 | Viking Therapeutics, Inc. |
| NCT06068946 | Phase 2 | Aug 31, 2023 | Viking Therapeutics, Inc. |
| NCT05203237 | Phase 1 | Dec 14, 2021 | Viking Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. | For profit | 5 | 5 | 3 | 2021 |
1 organizations
Page 1 / 1